Clene, Inc. (CLNN)
3.92
-0.08
(-2.00%)
USD |
NASDAQ |
Nov 13, 16:00
3.92
0.00 (0.00%)
After-Hours: 19:59
Clene Enterprise Value : 68.44M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 68.44M |
| November 12, 2026 | 69.57M |
| November 11, 2026 | 72.34M |
| November 10, 2026 | 75.40M |
| November 09, 2026 | 74.97M |
| November 06, 2026 | 68.86M |
| November 05, 2026 | 69.15M |
| November 04, 2026 | 70.99M |
| November 03, 2026 | 66.30M |
| November 02, 2026 | 64.03M |
| October 30, 2026 | 67.16M |
| October 29, 2026 | 68.15M |
| October 28, 2026 | 70.00M |
| October 27, 2026 | 69.15M |
| October 26, 2026 | 67.30M |
| October 23, 2026 | 67.87M |
| October 22, 2026 | 67.87M |
| October 21, 2026 | 66.16M |
| October 20, 2026 | 65.74M |
| October 19, 2026 | 59.48M |
| October 16, 2026 | 56.78M |
| October 15, 2026 | 59.69M |
| October 14, 2026 | 59.77M |
| October 13, 2026 | 60.90M |
| October 12, 2026 | 65.02M |
| Date | Value |
|---|---|
| October 09, 2026 | 67.58M |
| October 08, 2026 | 67.87M |
| October 07, 2026 | 68.44M |
| October 06, 2026 | 67.73M |
| October 05, 2026 | 68.29M |
| October 02, 2026 | 70.71M |
| October 01, 2026 | 69.86M |
| September 30, 2026 | 70.71M |
| September 29, 2026 | 65.06M |
| September 28, 2026 | 64.55M |
| September 25, 2026 | 67.62M |
| September 24, 2026 | 66.47M |
| September 23, 2026 | 67.49M |
| September 22, 2026 | 68.64M |
| September 21, 2026 | 70.69M |
| September 18, 2026 | 68.26M |
| September 17, 2026 | 65.70M |
| September 16, 2026 | 62.00M |
| September 15, 2026 | 64.04M |
| September 14, 2026 | 54.59M |
| September 11, 2026 | 58.29M |
| September 10, 2026 | 59.31M |
| September 09, 2026 | 60.21M |
| September 08, 2026 | 58.93M |
| September 04, 2026 | 61.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.108M |
| Brainstorm Cell Therapeutics, Inc. | 12.28M |
| Summit Therapeutics, Inc. | 10.71B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 27.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.915M |
| Revenue (Quarterly) | 0.056M |
| Total Expenses (Quarterly) | -3.859M |
| EPS Diluted (Quarterly) | 0.0487 |
| Gross Profit Margin (Quarterly) | -551.8% |
| Earnings Yield | -66.59% |
| Normalized Earnings Yield | -59.26 |